| Authors: |
Cordas Dos Santos DM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Toenges R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Bertamini L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Hematology, Erasmus MC Cancer Institute Rotterdam, Rotterdam, The Netherlands., Alberge JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. irene_ghobrial@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. irene_ghobrial@dfci.harvard.edu.; Broad Institute of Harvard and MIT, Cambridge, MA, USA. irene_ghobrial@dfci.harvard.edu. |
